# Section of Hematology and Medical Oncology

Newsletter



#### In This Issue:

- New Faculty: 2
- New Staff/Additions: 3
- Awards/Publications: 4
- Publications/Presentations: 5
- Presentations: 6-7
- Announcements: 8
- Upcoming Research Seminar: 9
- Upcoming Section Events: 10

# Racial Disparities A 'Harsh Reality' in Breast Cancer Care



Naomi Ko, MD, MPH, was interviewed by Healio and discussed how disparities in care disproportionately affect Black and Brown women with breast cancer, the need for better representation of these patient populations in clinical studies, ways to address these issues and more. Read more

Naomi Ko, MD, MPH





## **New Faculty**



Margaux Dockerty, RN, MSN, AGNP-C

Margaux Dockerty, RN, MSN, AGNP-C, joined the Section of Hematology & Medical Oncology on January 3, 2022 and will be supporting the Cellular Therapy, Stem Cell Transplant and the Red Blood Cell Programs. Maugaux joins us from Massachusetts General Hospital where she worked in the Urogynecology Department and the Division of Female Medicine & Reconstructive Surgery. Margaux was also a part of the COVID-19 Relief Response Team during the height of the pandemic and is conversational in Spanish.



Arielle Davidson, MS, ACNPC-AG, CCRN,

Arielle Davidson, MS, ACNPC-AG, CCRN, joins the Section of Hematology & Medical Oncology on February 1, 2022. Arielle joins us from the Neurosciences Intensive Care Unit at Boston Medical Center where she has worked for just over two years and is also fluent in Spanish, French, and Portuguese.



Annie Helmkamp, MSN AGPCNP-BC

Annie Helmkamp, MSN, AGPCNP-BC, joins the Section of Hematology & Medical Oncology on February 1, 2022. Annie joins us from the Occupational Health department at Boston Medical Center where she has worked for just under two years and is currently enrolled in beginner's medical Spanish at the Boston Medical Spanish Center.



#### **New Staff**




Joakin Mori, PhD

Joakin Mori, PhD, joins the Heaphy Lab as a Postdoctoral Research Fellow. Dr. Mori recently received his Ph.D. from Tuskegee University where he investigated molecular and pathological alterations that may help explain the observed racial disparities in prostate cancer outcomes.

Congratulations to Chris Heaphy, PhD, and family for welcoming

#### **New Additions**



Xena Yvonne Zammit



Ayden Ton Heaphy





Ayden Ton Heaphy on 12/9/21!

#### **Awards**



Andrew Staron, MD

Chief Fellow Andrew Staron, MD, was the recipient of the ASH Abstract Achievement Award, a merit-based award for trainees who are the first author and presenter of a high-scoring annual meeting abstract.

#### **Publications**



Camille Edwards, MD

Camille Edwards, MD, and colleagues published <u>Phase 1a/b study</u> of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.

Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039. PMID: 34521113; PMCID: PMC8703360.





## **Publications**





Hamza Hassan, MD, and Vaishali Sanchorawala, MD, published Beyond Survival in AL Amyloidosis: Identifying and Satisfying Patients' Needs

Hassan H, Sanchorawala V. Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients' Needs. Hemato. 2022; 3(1):38-46. https://doi.org/10.3390/hemato3010004

Hamza Hassan, MD

Vaishali Sanchorawala, MD

### **Presentations**



Andrew Staron, MD

Andrew Staron, MD, was selected for an oral presentation at ASH and gave a talk titled, "A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis," during the session "Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want."





#### **Presentations**



Vaishali Sanchorawala, MD, was a clinical discussant at the ASH Conference and gave a talk titled, "Treatment Landscape for AL Amyloidosis," during the session "ASH-FDA Join Symposium on Newly Approved Drugs: Treatment Advances in Rare Diseases."

Vaishali Sanchorawala, MD



Andrew Staron, MD

Andrew Staron, MD, presented the poster "Longitudinal Assessment and Prognostic Importance of Minimal Residual Disease (MRD) by Multiparametric Flow Cytometry in Patients with Systemic Light Chain (AL) Amyloidosis" at the ASH Conference.

Camille Edwards, MD, presented the poster "Peripheral Blood Monocyte Count is a Strong, Dynamic Prognostic Biomarker for Risk Stratification in Multiple Myeloma" at the ASH Conference.





#### **Presentations**



David Hughes, PharmD

David Hughes, PharmD, presented the poster "Successful Conversion and Implementation to Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis" at the ASH Conference.

Raphael Szalat, MD, PhD, presented the poster "Predictive Factors

Treated with Single Agent Daratumumab" at the ASH Conference.

of Overall Survival in Patients with Relapsed AL Amyloidosis



Raphael Szalat, MD, PhD





#### To all members in the Hem Onc section and Cancer Center,

As part of the Hem Onc Anti-Racism Initiatives, we conduct a yearly Diversity and Inclusion Climate survey in order to assess our progress in fostering a culture of respect, inclusion, and belonging. We hope that everyone in our community will participate in this brief anonymous survey. Our Equity and Wellness Champion, Laura Lowery, will compile the results and present them at a future section meeting.

This survey will only take a few minutes of your time. Please submit it by Friday January 28. <a href="https://forms.gle/eL9xx7AoT2riGab26">https://forms.gle/eL9xx7AoT2riGab26</a>
You can access it on your phone by using this QR code:



Thank you for your time and help in fostering a supportive, diverse, and inclusive community for everyone here in HemOnc.

If you have any questions regarding the survey, please feel free to contact Laura Lowery at <a href="mailto:lalowery@bu.edu">lalowery@bu.edu</a> or 617-767-9082.

**HemOnc Anti-Racism Committee** 

# **Upcoming Research Seminar**



# Heme/Onc Research Seminar

#### Tuesday January 25th at 3PM (hybrid)

Zoom: https://bostonu.zoom.us/i/94031312565?pwd=cC9RTzB0TEFidVBKRIN1OUJJb0ViQT09 In person: X715, EBRC (650 Albany Street, 7th floor)

Triple Negative Breast Cancer, from patient to microscope: "May multi-omics be with you"



Dr. Naomi Ko, MD



Dr. Ruben Dries, PhD



## **Upcoming Section Events**

1/25/22, 3:00pm: Heme/Onc Research Seminar

Join Zoom Meeting: https://bostonu.zoom.us/j/94031312565?

pwd=cC9RTzB0TEFjdVBKRIN1OUJJb0VjQT09

Meeting ID: 940 3131 2565

Passcode: 363220

1/27/22, 12pm: Cancer Center Grand Rounds: Best of ASH Conference Join Zoom Meeting: <a href="https://bostonmedicalcenter.zoom.us/j/93827852365?">https://bostonmedicalcenter.zoom.us/j/93827852365?</a>

pwd=eUxtUVd3eFc0bVNkVHl3TXc5Rk13Zz09

Meeting ID: 938 2785 2365

Passcode: 352705

#### Follow Us on Instagram!



Hematology & Medical Oncology is officially LIVE on Instagram! Follow us at @BMCHemOnc

If you or one of your patients would like to be featured, please submit a request at <a href="https://www.bumc.bu.edu/hematology/announcement-requests/">https://www.bumc.bu.edu/hematology/announcement-requests/</a>

#### Available Career Opportunities as of December 2021:

- Clinical Investigator, Genitourinary Oncology Program
- Clinical Investigator, Hematology/Hematologic Malignancies
- · Research Assistant
- · Advanced Fellow in Sickle Cell Disease
- Clinical Research Nurse
- Clinical Research Coordinator



